Company intelligence / Profile preview

Aclipse Two

Radnor, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Gastroparesis (M107): Phase 2-ready, oral small molecule (lobeglitazone/M107), disease-modifying approach targeting inflammation and cell repair; successful Pre-IND FDA meeting, extensive safety record from >3,600 exposures, potential first-in-class. ALS (M102): Entering Phase 1, oral small molecule, dual NRF2/HSF1 activation, promising animal model results (motor neuron protection, functional improvement), precision medicine approach for patient stratification.

Therapeutic areas: NeurologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Partnerships

Chong Kun Dang Pharmaceutical Corporation (licensing partner for lobeglitazone/M107)Sheffield Institute for Translational Neurosciences (SITraN, UK; research/clinical collaboration for ALS program)

Beyond the preview

Go deeper on Aclipse Two.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aclipse Two.

Explore the full profile